Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:31 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Brigatinib Before Brain Irradiation Trial (B3i Trial)
NCT04634110 · University of Colorado, Denver · PHASE2 · terminated · last registry update 2022-10-24 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low accrual” | Open Targets' class: insufficient enrollment | Registry record, University of Colorado, Denver |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ALK in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-10-13Phase 3 first posted: Shenzhen TargetRx Co., Ltd., TGRX-326 + Crizotinib (NCT06082635)
- 2023-08-14Phase 3 first posted: Medicine Invention Design, Inc, ALECENSA - alectinib hydrochloride capsule (NCT05987956)
- 2023-07-07Also stopped (terminated): Pfizer, Avelumab + PF-06463922 (NCT02584634)
- 2023-02-03Also stopped (terminated): University of Texas Southwestern Medical Center, Ceritinib (NCT02513667)
- 2023-01-27Results posted on the registry: Takeda, Midazolam + Brigatinib (NCT03420742)
- 2023-01-26Results posted on the registry: Criterium, Inc., brigatinib (NCT02706626)
- 2023-01-26Also stopped (terminated): Criterium, Inc., brigatinib (NCT02706626)
- 2022-12-27Also stopped (terminated): University of California, San Francisco, Ceritinib + Trametinib (NCT03087448)
- 2022-10-17Also stopped (terminated): University of California, San Francisco, Binimetinib + Brigatinib (NCT04005144)
- 2022-04-22Phase 3 first posted: Betta Pharmaceuticals Co., Ltd., Ensartinib + Placebo (NCT05341583)
- 2022-02-11Results posted on the registry: University of Colorado, Denver, Crizotinib (NCT03088930)
- 2022-02-09Results posted on the registry: Pfizer, Avelumab + PF-06463922 (NCT02584634)
- 2022-01-24Phase 3 first posted: Xuanzhu Biopharmaceutical Co., Ltd., XZP-3621 + Crizotinib (NCT05204628)
- 2021-12-27Phase 3 first posted: Hoffmann-La Roche, Alectinib + Entrectinib (NCT05170204)
- 2021-12-17Results posted on the registry: University of Texas Southwestern Medical Center, Ceritinib (NCT02513667)
- 2021-12-14Results posted on the registry: Takeda, Brigatinib (NCT03410108)
- 2021-10-26Results posted on the registry: Pfizer, Lorlatinib (NCT03909971)
- 2021-10-25Results posted on the registry: Ariad Pharmaceuticals, Brigatinib (NCT03535740)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision